Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949211 | 0.95 | HTR6 (0.47) | HTR6HCRTR1HCRTR2ALOX5CYP19A1 | |
| SCHEMBL9948910 | 0.91 | HTR6 (0.49) | HTR6ALOX5CYP19A1ALKCYP3A4 | |
| SCHEMBL2131067 | 0.84 | HTR6 (0.49) | HTR6HCRTR1HCRTR2ALOX5CYP19A1 | |
| SCHEMBL2023408 | 0.83 | HTR6 (0.56) | HTR6HCRTR1HCRTR2CYP19A1ALK | |
| SCHEMBL2131523 | 0.80 | HCRTR2 (0.50) | HTR6HCRTR1HCRTR2CYP19A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL9949887 | 0.79 | HTR6 (0.53) | HTR6HCRTR1HCRTR2CYP19A1ALK | |
| SCHEMBL2132944 | 0.79 | HCRTR2 (0.55) | HTR6HCRTR1HCRTR2CYP19A1 | |
| SCHEMBL2027090 | 0.78 | HTR6 (0.46) | HTR6ALOX5CYP19A1ALKBCHE | |
| SCHEMBL2024166 | 0.77 | HCRTR2 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL15247171 | 0.77 | HCRTR2 (0.72) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516439-B1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| EP-2632924-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2013-09-04 | — | — | EP | disclosed |
| EP-2516439-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| WO-2012055888-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012055888-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| WO-2011076747-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076747-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | REN, PKD1, NR3C2 | HTR6 1518/4885HCRTR1 3548/4885HCRTR2 3205/4885 |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | HTR6 209/4885HCRTR1 2/4885HCRTR2 1/4885 |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | REN, PKD1, NR3C2 | HTR6 1605/4885HCRTR1 3936/4885HCRTR2 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.